Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print      Mail a friend       Annual reports

Friday 13 April, 2012

Hikma Pharmaceutical

Annual Financial Report & AGM Notice

RNS Number : 2998B
Hikma Pharmaceuticals Plc
13 April 2012


Hikma Pharmaceuticals PLC

2011 Annual Report & Accounts and Notice of 2012 Annual General Meeting

In compliance with Listing Rule 9.6.1, Hikma Pharmaceuticals PLC has submitted copies of the documents listed below to the National Storage Mechanism and will shortly be available for inspection at or

·        Annual Report & Accounts 2011

·        Notice of 2012 Annual General Meeting

·        Proxy forms for the 2012 Annual General Meeting

Copies of the Annual Report and Notice of Meeting will also be available on our website Hard copies are available by writing to the Company Secretary, Hikma Pharmaceuticals PLC, 13 Hanover Square, London W1S 1HW or by attending the office in person.

The Annual General Meeting will be held at 11:00 am on Thursday 17 May 2012 at The Westbury, Bond Street, Mayfair, London W1S 2YF.

In accordance with DTR 6.3.5, this announcement contains information in the attached Appendices of the principal risk factors (Appendix 1), a responsibility statement (Appendix 2) and details of related party transactions (Appendix 3) which has been extracted in full unedited text from the Annual Report and Accounts 2011.  Where page numbers and notes are mentioned in the Appendix these refer to page numbers and notes in the Annual Report and Accounts 2011. 



Hikma Pharmaceuticals PLC                                           Tel: +44 (0)20 7399 2760

Peter Speirs, Company Secretary                             

Susan Ringdal, Investor Relations Director

Financial Dynamics                                              Tel:  +44 (0)20 7831 3113

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole    


About Hikma

Hikma is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and nonbranded generic and inlicensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

Appendix 1 - Principal Risks and Uncertainties

The Group's business faces risks and uncertainties. 


The section below includes the principal risks and uncertainties that the Group considers could have a significant effect on its financial condition, results of operations or future performance.  The list is not set out in order of priority and other risks, currently unknown or not considered material, could have a similar effect.


Operational risks



Potential impact


Compliance with regulatory requirements

>          Failure to comply with applicable regulatory requirements and manufacturing standards (often referred to as 'Current Good Manufacturing Practices' or cGMP)

>          Delays in supply or an inability to market or develop the Group's products


>          Delayed or denied approvals for the introduction of new products


>          Product complaints or recalls


>          Bans on product sales or importation


>          Disruptions to operations


>          Potential for litigation


>          Commitment to maintain the highest levels of quality across all manufacturing facilities


>          Strong global compliance function that oversees compliance across the Group


>          Remuneration and reward structure that helps retain experienced personnel


>          Continuous staff training and know-how exchange


>          On-going development of standard operating procedures


Regulation changes

>          Unanticipated legislative and regulatory actions, developments and changes affecting the Group's operations and products

>          Restrictions on the sale of one or more of our products 


>          Restrictions on our ability to sell our products at a profit


>          Unexpected additional costs required to produce, market or sell our products


>          Increased compliance costs


>          Strong oversight of local regulatory environments to help anticipate potential changes


>          Local operations in [all] of our key markets


>          Representation and/or affiliation with local industry bodies


>          Diverse geographical and therapeutic business model

Commercialisation of new products

>          Delays in the receipt of marketing approvals, the authorisation of price and re-imbursement


>          Lack of approval and acceptance  of new products by physicians, patients and other key decision-makers


>          Inability to confirm safety, efficacy, convenience and/or  cost-effectiveness of our products as compared to competitive products


>          Inability to participate in tender sales

>          Slowdown in revenue growth from new products


>          Inability to deliver a positive return on investments in R&D, manufacturing and sales and marketing


>          Experienced regulatory teams able to accelerate submission  processes across all of our markets


>          Highly qualified sales and marketing teams across all markets


>          A diversified product pipeline with over [60] new compounds pending approval, covering a broad range of therapeutic areas


>          A systematic commitment to quality that helps to secure approval and acceptance of new products and mitigate potential safety issues

Product safety

>          Unforeseen product safety issues for marketed products, particularly in respect of in-licensed products

>          Interruptions to revenue flow


>          Costs of recall, potential for litigation


>          Reputational damage



>          Diversification of product portfolio across key markets and therapies


>          Working with stakeholders to understand issues as they arise

Product development

>          Failure to secure new products or compounds for development

>          Inability to grow sales and increase profitability for the Group


>          Lower return on investment in research and development


>          Experienced and successful in-house R&D team, with specifically targeted product development pathways


>          Continually developing  and multi-faceted approach to new product development


>          Strong business development team


>          Track record of building in-licensed brands


>          Position as licensee of choice for our key MENA geography


Co-operation with Third parties

>          Inability to renew or extend in-licensing or other co-operation  agreements  with third parties

>          Loss of products from our portfolio


>          Revenue interruptions


>          Failure to recoup sales and marketing and business development costs



>          Investment in long-term relationships with existing in-licensing partners


>          Experienced legal team capable of negotiating robust agreements with our partners


>          Continuous development of new partners for licensing and co-operation


>          Diverse revenue model with in-house R&D capabilities



Increased competition

>          New market entrants in key geographies


>          On-going pricing pressure in increasingly commoditised markets


>          Loss of market share


>          Decreasing revenues on established portfolio


>          On-going portfolio diversification, differentiation and renewal through internal R&D, in-licensing and product acquisition


>          Continuing focus on expansion of geographies and therapeutic areas

Disruptions in the manufacturing supply chain

>          Inability to procure active ingredients from approved sources


>          Inability to procure active ingredients on commercially viable terms


>          Inability to procure the quantities of active ingredients  needed to meet market requirements



>          Inability to develop and/or commercialise new products


>          Inability to market existing products as planned


>          Lost  revenue streams on short notice


>          Reduced service levels and damage to customer relationships


>          Inability to supply finished product to our customers in a timely fashion




>          Alternate approved suppliers of  active ingredients


>          Long-term relationships with reliable raw material suppliers


>          Corporate auditing team continuously monitors regulatory compliance of API suppliers


>          Focus on improving service levels and optimising our supply chain

Economic and political and unforeseen events

>          The failure of control, a change in the economic conditions or political environment or sustained civil unrest in any particular market or country


>          Unforeseen events such as fire or flooding could cause disruptions to manufacturing or supply

>          Disruptions to manufacturing and marketing plans


>          Lost revenue streams


>          Inability to market or supply products

>          Geographic diversification, with 9 manufacturing facilities and sales in more than 40 countries


>          Product diversification, with 423 products and 817 dosage strengths and forms



>          Commercial, product liability and other claims brought against the Group

>          Financial impact on Group results from adverse resolution of proceedings


>          Reputational damage

>          In-house legal counsel with relevant jurisdictional experience



Financial risks





Foreign exchange risk

>          Exposure to foreign exchange movements, primarily in the Euro, Algerian dinar, Sudanese pound and Egyptian pound

>          Fluctuations in the Group's net asset values and profits upon translation into US dollars

>          Entering into currency derivative contracts where possible


>          Foreign currency borrowing


>          Matching foreign currency revenues to in-jurisdiction costs 

Interest rate risk

>          Volatility in interest rates

>          Fluctuating impact on profits before taxation

>          Optimisation of fixed and variable rate debt as a proportion of our total debt


>          Use of interest rate swap agreements



Credit Risk

>          Inability to recover trade receivables


>          Concentration of significant trade balances with key customers in the MENA region and the US


>          Reduced working capital funds


>          Risk of bad debt or default

>          Clear credit terms for settlement of sales invoices


>          Group Credit policy limiting credit exposures


>          Use of various financial instruments such as letters of credit, factoring and credit insurance arrangements


Liquidity Risk

>          Insufficient free cash flow and borrowings headroom

>          Reduced liquidity and working capital funds


>          Inability to meet short-term working capital needs and, therefore, to execute our long term strategic plans

>          Continual evaluation of headroom and borrowing


>          Committed debt facilities


>          Diversity of institution, subsidiary and geography of borrowings



>      Changes to tax laws and regulations in any of the markets in which we operate

>      Negative impact on the Group's effective tax rate


>      Costly compliance requirements

>      Close observation of any intended or proposed changes to tax rules, both in the UK and in other key countries where the Group operates


Appendix 2 - Responsibility Statement


The directors are responsible for preparing the Annual Report and the financial statements. The Directors are required to prepare financial statements for the Group in accordance with International Financial Reporting Standards as adopted by the European Union ("IFRS") and have also elected to prepare financial statements for the Company in accordance with the IFRS under EU law. Company law requires the Directors to prepare such financial statements in accordance with IFRS, the Companies Act 2006 and Article 4 of the International Accounting Standard ("IAS") Regulations.

IAS 1 requires that financial statements present fairly for each financial year the company's financial position, financial performance and cash flows. This requires the faithful representation of the effects of transactions, other events and condition in accordance with the definitions and recognition criteria for assets, liabilities, income and expenses set out in the International Accounting Standards Board's 'Framework for the Preparation and Presentation of Financial Statements'. In virtually all circumstances, a fair presentation will be achieved by compliance with all applicable IFRS. Directors are also required to:

·           Properly select and apply accounting policies

·           Present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information

·           Provide additional disclosures when compliance with the specific requirements in IFRS is insufficient to enable users to understand the impact of particular transactions, other events and conditions on the entity's financial position and financial performance

·           Make an assessment of the company's ability to continue as a going concern

The directors are responsible for keeping proper accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the Company, for safeguarding the assets, for taking reasonable steps for the prevention and detection of fraud and other irregularities and for the preparation of a directors' report and directors' remuneration report which comply with the requirements of the Companies Act 2006.

The directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements differs from legislation in other jurisdictions.

We confirm to the best of our knowledge:

·           The financial statements, prepared in accordance with International Financial Reporting Standards as adopted by the EU, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; and

·           The business review, which is incorporated into the Directors' Report, includes a fair review of the development and performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties they face.


By order of the Board


Said Darwazah                         Mazen Darwazah

Chief Executive Officer              Executive Vice Chairman, CEO MENA

13 March 2012


Appendix 3 - Related Party Transactions

Details of related party transactions are included in Note 38 of the Financial Statements on pages 138 to 139.

Transactions between the Company and its subsidiaries have been eliminated on consolidation and are not disclosed in this note. Transactions between the Group and its associate and other related parties are disclosed below.


Trading transactions:

During the year, Group companies entered into the following transactions with related parties:


Darhold Limited: is a related party of the Group because it is considered one of the major shareholders of Hikma Pharmaceuticals PLC with ownership percentage of 29.2% at the end of 2011 (2010: 29.5%). Further details on the relationship between Mr. Samih Darwazah, Mr. Said Darwazah, Mr. Mazen Darwazah and Mr. Ali Al-Husry, and Darhold Limited are given in the Directors' Report. Other than dividends (as paid to all shareholders), there were no transactions between the Group and Darhold Limited in the year.


Capital Bank - Jordan: is a related party of the Group because during the year two board members of the Bank were also Board members at Hikma Pharmaceuticals PLC. Total cash balances at Capital Bank - Jordan were US D 610,000 (2010: USD 2,169,000). Loans and overdrafts granted by Capital Bank to the Group amounted to US D 3,841,000 (2010: US D 48,000) with interest rates ranging between 8.25% and 3MLI BOR + 1. Total interest expense incurred against Group facilities was US D 7,000 (2010: US D 18,000). Total interest income received was Nil (2010: US D 8,000) and total commission paid in the year was US D 8,000 (2010: US D 76,000).


Jordan International Insurance Company: is a related party of the Group because one Board member of the Company is also a Board member at Hikma Pharmaceuticals PLC. Total insurance premiums paid by the Group to Jordan International Insurance Company during the year were US D 3,035,000 (2010: US D 2,166,000). The Group's insurance expense for Jordan International Insurance Company contracts in the year 2011 was US D 2,902,000 (2010: US D 2,481,000). The amounts due from Jordan International Insurance Company at the year end were US D 109,000 (2010: Due to US D 66,000).


Mr. Yousef Abd Ali: is a related party of the Group because he holds a non-controlling interest in Hikma Lebanon of 33%, the amount owed to Mr. Yousef by the Group as at 31 December 2011 was US D 150,000 (2010: US D 161,000).


Labatec Pharma: is a related party of the Group because it is owned by Mr. Samih Darwazah. During 2011 the Group total sales to Labatec Pharma amounted to US D 338,000 (2010: US D 414,000) and the Group total purchases from Labatec amounted to US D 3,805,000 (2010: US D 1,373,000). At 31 December 2011 the amount owed to Labatec Pharma from the Group was US D 753,000 (2010: US D 193,000).


King and Spalding: is a related party of the Group because the partner of the firm is a board member and the company secretary of West-Ward. King and Spalding is an outside legal counsel firm that handles general legal matters for West-Ward. During 2011 fees of US D 1,216,000 (2010: US D 927,000) were paid for legal services provided.


Remuneration of key management personnel

The remuneration of the key management personnel (comprising the Executive and Non-Executive Directors' and certain of senior management as set out in the Directors' Report) of the Group is set out below in aggregate for each of the categories specified in IAS 24 Related Party Disclosures. Further information about the remuneration of the individual directors is provided in the audited part of the Remuneration Committee Report on pages 76 to 90.






Short-term employee benefits




Share-based payments




Post-employment benefits



Other benefits






* See Note 2.



This information is provided by RNS
The company news service from the London Stock Exchange